AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01206478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Amitriptyline 1 mg/kg once daily at bedtime.
Study NCT01206478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
Study NCT01206478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol
Description: At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
Study NCT01206478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol
Description: At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
Study NCT04205968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV bolus or IV
Study NCT04205968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT04205968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT04205968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT02658513 — intervention group
Intervention type: OTHER
Intervention: Lancet blood sampling
Description: Blood samples will be obtained using a finger-prick (lancet) technique.
Study NCT02658513 — intervention group
Intervention type: OTHER
Intervention: Standard intravenous blood sampling
Description: Blood samples will be obtained using a standard intravenous technique.
Study NCT03250299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microtubule-Targeted Agent BAL101553
Description: Given PO
Study NCT03250299 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02334111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESPECT-Plus
Description: A RESPECT-Plus family specialist (FS) will deliver the intervention to subjects (mothers in treatment for opiate use disorder) recruited during their third trimester of pregnancy and randomized into the study's intervention arm post-delivery. During their infant's hospital stay, the FS will schedule a convenient time to meet the subjects (mothers) to educate them on infant soothing techniques. With permission from the mother, the FS will join the subjects during their infant's routine well-child visits at the pediatric primary site. Optional home visiting provides another meeting opportunity between the subjects and FS.
Study NCT02519621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT PRO without irrigation
Description: NPWT PRO without irrigation.
Study NCT02519621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT PRO with irrigation
Description: NPWT PRO with irrigation (saline)
Study NCT02519621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KCI Ulta
Description: KCI Ulta NPWT without irrigation
Study NCT02744131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate
Study NCT02744131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1500mgs per day
Study NCT01712919 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Patients will be given intensity-modulated radiotherapy(IMRT)
Study NCT01712919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy with paclitaxel and nedaplatin
Description: Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
Study NCT01712919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Patients will be given cetuximab weekly during radiation therapy
Study NCT03295695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluoro-D-glucose-positron Emission Tomography
Description: 2-deoxy-2-\[18F\]Fluoro-D-glucose-positron Emission Tomography (FDG-PET): within 2 weeks of obtaining first echocardiogram; within two weeks of obtaining follow-up echocardiogram.
Study NCT03295695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)
Description: 2-deoxy-2-\[18F\]fluoro-D-glucose (FDG) labeled autologous human erythrocytes (RBCs): Approximately 10 mls of packed human erythrocytes are collected from the patient and labeled with ≈5-10 milliCuries of commercially available United States Pharmacopeia (USP)-grade FDG (≈5-10 picograms FDG) (Vendor: Cardinal Health) under sterile conditions in a Good Manufacturing Practice (GMP)-certified laboratory.~Synthesized RBCs: The cell suspension is manually infused via syringe through an indwelling peripheral venous catheter over the course of 1 minute, using an infusion method approved by the Moffitt Cancer Center (MCC) radiation safety officer.
Study NCT03295695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: Echocardiogram: prior to start of chemotherapy; post-treatment regimen.
Study NCT03336957 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal treatment
Description: non-surgical periodontal therapy (NPT) consisted of scaling, root planning, and oral hygiene instruction
Study NCT03336957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal treatment
Description: non-surgical periodontal therapy (NPT) consisted of scaling, root planning, and oral hygiene instruction
Study NCT00062751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole / Temsirolimus (CCI-779)
Description: Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily
Study NCT00062751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole / Temsirolimus (CCI-779)
Description: Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks
Study NCT00062751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg daily
Study NCT01427166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non invasive venous ultrasound
Description: Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
Study NCT04519970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Each tier will have a different level of case management and support, all with the goal of increasing adherence to Biktarvy for HIV management.
Study NCT00214266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H®, Rituximab, mycophenolate mofetil
Description: Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
Study NCT01230736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)
Description: One drop in study eye(s) once daily for 8 weeks
Study NCT05127070 — intervention group
Intervention type: DEVICE
Intervention: Neotree
Description: The Neotree is a digital app, data collection and quality improvement system. collecting and collating routine health data at the bedside for babies on admission and discharge and for laboratory results. it provides point of care education and clinical decision support to optimise the clinical care of sick and vulnerable newborns according to approved and best available clinical guidelines.
Study NCT03580291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: The group receive pulse infusion of MSCs once of 2 x 10\^6/kg body weight
Study NCT03580291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: This group receive oral MMF of 2.0 g / d.
Study NCT03580291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Mesenchymal stem cells
Description: The group receive placebo of Mesenchymal stem cells.
Study NCT03894085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine treatment for 4 weeks usage:20-80mg Qd
Study NCT03580291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Mycophenolate Mofetil
Description: The group receive placebo of oral mycophenolate mofetil.
Study NCT00102687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation.
Study NCT03384017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation and Gait Training
Description: TSCS will be applied using a midline electrode placed on the skin between spinous process T11 -T12 and two electrodes placed symmetrically on the skin over the lower abdomen as anodes. A symmetrical biphasic rectangular waveform, at 50 Hz and 1 millisecond, is used to provide 30 continuous minutes of stimulation.~Subjects will participate in 24 two-hour sessions of physical therapy over eight weeks. In each session, subjects will receive TSCS continuously for 30 minutes, using the parameters outlined above. During stimulation, subjects will participate in strengthening, segmental task practice, and gait-based interventions. Participation in gait training will continue following the stimulation period for the duration of the session.
Study NCT04890080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Exercise training consisted of supervised breathing, aerobic, strengthening and stretching exercises for 8 weeks, 2 days a week. Breathing exercises included pursed lip, diaphragmatic, thoracic expansion and basal expansion exercises. Strength training included the lower and upper extremities, and it was performed 8-10 repetitions, either against gravity or using free weight, according to patient tolerance.
Study NCT02046668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: spironolactone
Description: spironolactone 25mg daily for 12 weeks
Study NCT02046668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: spironolactone 25mg daily for 12 weeks
Study NCT02892903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Routine Measurement of FFR
Description: FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow \<3 will not be examined but will be 'awarded' an FFR value of 0.5
Study NCT01449422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dressing
Description: the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
Study NCT02226731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early Belfort-Dildy Balloon
Description: Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization at the same time as the second line uterotonic treatment.
Study NCT02226731 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Late Belfort-Dildy balloon
Description: Intrauterine tamponade with the Belfort-Dildy balloon, performed if failure of second line uterotonic treatment, ie persisting bleeding 30 minutes after the beginning of this infusion.
Study NCT01449422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
Study NCT00648726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime plus erythromycin
Description: intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
Study NCT00648726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin (Zithromax)
Description: intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
Study NCT00648726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime
Description: intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
Study NCT02810184 — intervention group
Intervention type: RADIATION
Intervention: cone-beam computed tomography (CBCT)
Description: additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
Study NCT02067949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube
Study NCT01304277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: agalsidase alfa
Study NCT02060669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Xeloda
Study NCT03967626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external cooling with the xxxxx device
Description: external cooling with the xxxxx device
Study NCT03967626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: external cooling with the xxxxx device
Description: external cooling with the xxxxx device
Study NCT00824135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: One dose intravenously every 24 hrs for five days total.~Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous
Study NCT00824135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation, Hematopoietic
Description: Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
Study NCT00824135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OKT3
Description: Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total~Muromonab-CD3
Study NCT00824135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg/day intravenous every 12 hours (2 doses total)
Study NCT00824135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60mg/m2 intravenous every 12 hours for 2 doses total.
Study NCT00824135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 600 mg/m2 intravenous two times a day~(continue for approximately 2 months or as clinically indicated)
Study NCT00824135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 intravenous for 1 dose total
Study NCT00824135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
Study NCT00656721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flutter Valve
Description: Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.~In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done.
Study NCT03551535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitored, At-Home Exercise Intervention
Description: Patients will be enrolled in the BurnAlong program as well as receive FitBit heart rate + activity monitors to track adherence rates to the prescribed exercise regimen on BurnAlong, with subsequent motivational interventions triggered if compliance varies from prescription
Study NCT02514278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy Folfirinox, 4 cycles
Description: * oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~* 5FU: 2400 mg/m2
Study NCT02514278 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 50 Gy, 2 Gy/session; 25 fractions
Description: Radiochemotherapy 5 weeks
Study NCT02514278 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 50 Gy, 2 Gy/session; 25 fractions
Description: Radiochemotherapy 5 weeks
Study NCT02514278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local excision in good responders
Description: If local excision:~* Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~* Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1.
Study NCT02514278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local excision in good responders
Description: If local excision:~* Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~* Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1.
Study NCT02514278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal excision in bad responders
Study NCT02514278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal excision in bad responders
Study NCT03353753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCC-2618
Description: Oral KIT/PDGFRA kinase inhibitor
Study NCT03353753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT02704494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol 500mg daily
Study NCT02704494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule daily
Study NCT02704494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losartan
Description: Losartan 12.5mg daily
Study NCT02704494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 12.5mg daily
Study NCT04626193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid
Study NCT04626193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
Study NCT02540096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice
Description: The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups).
Study NCT02540096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive training and Relaxation
Description: Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
Study NCT03721393 — intervention group
Intervention type: DEVICE
Intervention: Wearable heart monitor
Description: Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.
Study NCT04413643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilation
Description: The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization. It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay. Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 >45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life. Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality.